Takeda says Phase 3 trial shows zasocitinib tops Bristol Myers’ deucravacitinib in plaque psoriasis

• Takeda disclosed new Phase 3 psoriasis data on investigational oral TYK2 inhibitor zasocitinib, presented at the EADV Congress 2026.
• Head-to-head results showed stronger skin-clearance outcomes versus Bristol Myers Squibb’s deucravacitinib, with earlier responses.
• Separate pivotal Phase 3 updates indicated responses held over longer follow-up, with faster patient-reported itch and quality-of-life improvement.
• Safety remained consistent across trials, with no new signals flagged in the latest readouts.
• Zasocitinib is under FDA and EMA review for moderate-to-severe plaque psoriasis, positioning it as a potential new once-daily oral option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260929022019) on September 30, 2026, and is solely responsible for the information contained therein.